NOTICE – The Fonds de recherche du Québec (FRQ) was established on June 1, 2024, in accordance with the Act to amend the Act respecting the Ministère de l’Économie et de l’Innovation with respect to research. The Fonds de recherche du Québec – Nature et technologies (FRQNT), the Fonds de recherche du Québec – Santé (FRQS) and the Fonds de recherche du Québec – Société et culture (FRQSC) have since been regrouped into the new FRQ, which continues their existence. The rights and obligations of the FRQNT, FRQS and FRQSC have become those of the FRQ; activities continue as usual.

Please note that if you come across an old name or logo of one of the Fonds de recherche du Québec in the program rules or on the website, it should now read as follows:

  • The FRQNT becomes the Nature et technologies sector;
  • The FRQS becomes the Santé sector;
  • The FRQSC becomes the Société et culture sector.

Thank you for your understanding.

Rémi

Chief scientist officer

remi.quirion@frq.gouv.qc.ca

On September 1, 2011, Rémi Quirion, OC, PhD, CQ, FRSC, became Québec’s first chief scientist. As such, he chairs the boards of directors of the three Fonds de recherche du Québec and advises the Minister of Economy, Science and Innovation on research and scientific development issues.

Until his appointment as chief scientist, Rémi Quirion was the vice-dean for science and strategic initiatives in the faculty of medicine at McGill University and senior university advisor on health sciences research. He was the scientific director of the Douglas Mental Health University Institute Research Centre, a full professor in the department of psychiatry at McGill University and the executive director of the International Collaborative Research Strategy for Alzheimer’s Disease of the Canadian Institutes of Health Research. Professor Quirion was the first scientific director of the Institute of Neurosciences, Mental Health and Addiction (INMHA), one of Canada’s 13 health research institutes.

His work helped to elucidate the roles of the cholinergic system in Alzheimer’s disease, of neuropeptide Y in depression and memory and of the calcitonin gene-related peptide (CGRP) in pain and opiate tolerance. Rémi Quirion earned his PhD in pharmacology from Université de Sherbrooke in 1980 and carried out his postdoctoral training at the National Institute of Mental Health in the United States in 1983. He has over 650 publications in prominent scientific journals and is one of the most extensively cited neuroscientists in the world. He has received several awards and honours, including the Ordre national du Québec (Chevalier du Québec, CQ) in 2003, the Prix Wilder-Penfield (Prix du Québec) in 2004 and the Order of Canada (OC) in 2007. Mr. Quirion is also a member of the Royal Society of Canada.